Abstracts tagged "autoimmune diseases"

Abstract Number: 0840 • ACR Convergence 2022
Postoperative Risk of Immunosuppression in Rheumatic Disease Patients Undergoing Arthroscopy
Kinjal Vasvada, Laith Jazrawi and Jonathan Samuels, NYU Langone Health, New York, NY
Background/Purpose: Recent literature suggests that rheumatic disease patients hold most immunosuppressive (IS) medications before and after joint replacement surgery, to prevent infections and other complications.…
Abstract Number: 1134 • ACR Convergence 2022
Genome-wide Association Study Identifies Novel Loci for Leukopenia Among TPMT and NUDT15 Normal Metabolizers Taking Azathioprine
Jacy Zanussi, Puran Nepal, Alyson Dickson, Laura Daniel, Peter Straub, Tyne Miller-Fleming, Wei-Qi Wei, Adriana Hung, Nancy Cox, Vivian Kawai, Jonathan Mosley, Michael Stein, QiPing Feng, Ge Liu, Ran Tao and Cecilia Chung, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Azathioprine is a thiopurine drug used for the treatment of several inflammatory and autoimmune conditions. However, its use is limited due to side effects,…
Abstract Number: 1309 • ACR Convergence 2022
Evaluation of Preference and Efficacy in the Treatment of Glucocorticoid-induced Osteoporosis in Patients with Autoimmune Diseases Receiving Zoledronic Acid
Ji-Won Kim¹, Ju-Yang Jung¹, Hyoun-Ah Kim¹ and Chang-Hee Suh², ¹Ajou University School of Medicine, Suwon, Republic of Korea, ²Ajou University Hospital, Suwon, Republic of Korea
Background/Purpose: The most commonly used drugs for glucocorticoid-induced osteoporosis (GIOP) is bisphosphonates, which include oral alendronate and risedronate, and intravenous zoledronic acid. Among them, zoledronic…
Abstract Number: 1625 • ACR Convergence 2022
Single Cell and Spatial Transcriptomics Identifies Pathogenic Drivers of Sjogren’s Disease in Humans
Blake Warner¹, Thomas Pranzatelli², Paola Perez², Daniel Martin², Shyh-Ing Jang², Kalie Dominick², Eiko Yamada², Kevin Byrd³, Quinn Easter⁴, A. Darise Farris⁵, Christopher Lessard⁵, Amanda Oliver⁶, Raquel Bartolome-Casado⁶, Zohreh Khavandgar¹, Sarthak Gupta⁷, Sarah Teichmann⁶, Alan Baer⁸ and John Chiorini², ¹National Institutes of Health, Bethesda, MD, ²NIDCR, Bethesda, MD, ³American Dental Association, Scientific Research Institute, Gaithersburg, MD, ⁴American Dental Association, Gaithersburg, MD, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Wellcome Sanger Institute, Cambridgeshire, United Kingdom, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁸Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Sjogren's Disease(SjD) is a systemic autoimmune disease characterized by exocrine dysfunction. The pathogenesis is incompletely understood, but involves gene-environment interactions leading to infiltration of…
Abstract Number: 1763 • ACR Convergence 2022
Different Humoral but Similar Cellular Responses of Patients with Autoimmune Inflammatory Rheumatic Diseases Under Disease-modifying Anti-rheumatic Drugs After COVID-19 Vaccination
Ioana Andreica¹, Arturo Blazquez-Navarro², Jan Sokolar³, Moritz Anft⁴, Uta Kiltz⁵, Stephanie Pfaender⁶, Elena Vidal Blanco⁷, Timm Westhoff⁸, Nina Babel⁸, Ulrik Stervbo⁹ and Xenofon Baraliakos¹⁰, ¹Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, ²Charité Universitätsmedizin Berlin, Berlin Center for Advanced Therapies, Berlin, Germany, ³Rheumazentrum Ruhrgebiet Herne, Ruhr Universität Bochum, Herne, Germany, ⁴Marienhospital Herne - Klinik Mitte Medizinische Klinik I - Gastroenterologie, Nieren- und Hochdruckkrankheiten, Center for Translational Medicine and Immune Diagnostics Laboratory, Medical Department I, Herne and Ruhr-Universit t Bochum, Medical Department I, Bochum, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶Ruhr-Universität Bochum, Medical Department I, Bochum, Germany, ⁷Ruhr-University Bochum, Department of Molecular and Medical Virology, Bochum, Germany, ⁸Marienhospital Herne, Ruhr-University Bochum, Herne, Germany, ⁹Marienhospital Herne - Klinik Mitte Medizinische Klinik I - Gastroenterologie, Nieren- und Hochdruckkrankheiten, Center for Translational Medicine and Immune Diagnostics Laboratory, Medical Department I, Herne and Ruhr-Universität Bochum, Medical Department I, Bochum, Germany, ¹⁰Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: The interplay between humoral and cellular response after vaccination against SARS-CoV-2 in patients (pts.) with autoimmune inflammatory rheumatic diseases (AIRD) remains unknown. To investigate…
Abstract Number: 2087 • ACR Convergence 2022
Prospective Study of Clinical, Laboratory, and Patient-Reported Outcomes of Patients with Systemic Lupus Erythematosus Undergoing Total Hip and Total Knee Arthroplasty
David Fernandez, Insa Mannstadt, Mark Figgie, Peter Sculco, Jason Blevins, Caroline Siegel, Deanna Jannat-Khah, DrPH, MSPH, Carey Ford, Mikhail Olferiev, Dina Greenman, Kyriakos Kirou and Susan Goodman, Hospital for Special Surgery, New York, NY
Background/Purpose: Patients with SLE have doubled their utilization of THA and TKA, yet postoperative complications remain high. However, disease specific measures have not been assessed.…
Abstract Number: PP20 • ACR Convergence 2022
‘It Is Due to Stress’ – But Which Type of Stress? Cumulative childhood stress is a risk factor for autoimmune disease
Melissa Allman, Michigan State University, Meridian Charter Township, MI
Background/Purpose: Trauma can have profound detrimental influences on our health and well-being. I am tangibly familiar with how trauma can impact the individual due to…
Abstract Number: L07 • ACR Convergence 2021
Depletion of KLRG1+ T Cells in a First-in-human Clinical Trial of ABC008 in Inclusion Body Myositis (IBM)
Niti Goel¹, Dulce Soler-Ferran², Monette Coutreau², Jorge Escobar³, Kate Courtemanche², Merrilee Needham⁴ and Steven Greenberg⁵, ¹Abcuro, Inc.; Duke University, Durham, NC, ²Abcuro, Inc., Newton, MA, ³Abcuro, Inc., Hayward, CA, ⁴Perron Institute, Murdoch University, Perth, Australia, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Inclusion body myositis (IBM), a relentlessly progressive autoimmune skeletal muscle disease, has no effective available pharmacological therapy. A prominent feature of IBM on microscopy…
Abstract Number: L16 • ACR Convergence 2021
Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patients with Autoimmune or Inflammatory Rheumatic Diseases: A Retrospective Cohort Analysis from a U.S. Nationally-sampled Electronic Medical Record Data Repository
Jasvinder Singh¹, Namrata Singh², Alfred Anzalone³, Amy Olex⁴, Jing Sun⁵, Vithal Madhira⁶ and Rena Patel⁷, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Washington, Bellevue, WA, ³University of Nebraska, Omaha, NE, ⁴Virginia Commonwealth University, Richmond, VA, ⁵Johns Hopkins University, Baltimore, MD, ⁶Palila Software, Reno, NV, ⁷Unviersity of Washington, Seattle, WA
Background/Purpose: National U.S. data on breakthrough COVID-19 infection in people with autoimmune or inflammatory rheumatic diseases (AIRD) are limited. Our objective was to assess whether breakthrough COVID-19 infections were increased post-COVID-19-vaccination…
Abstract Number: 0095 • ACR Convergence 2021
Risk Factors for “Long Haul” COVID-19 in Rheumatology Outpatients in New York City
Medha Barbhaiya¹, Deanna Jannat-Khah¹, Jonah Levine¹, Huong Do¹, Jessica Gordon¹, Vivian Bykerk² and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²Division of Rheumatology, Hospital for Special Surgery, New York City, NY
Background/Purpose: COVID-19 ‘long-haulers’ are individuals who experience persistent symptoms after COVID-19 diagnosis. Whether this is of particular concern for rheumatic disease patients, due to their…
Abstract Number: 0189 • ACR Convergence 2021
Tapering and Discontinuation of Background Therapies During the Transition to Rilonacept Monotherapy in RHAPSODY, a Phase 3 Clinical Trial of Rilonacept in Patients with Recurrent Pericarditis
Antonio Brucato¹, Alistair Wheeler², Sushil A. Luis³, Antonio Abbate⁴, Paul Cremer⁵, Fang Fang⁶, Antonella Insalaco⁷, Martin LeWinter⁸, Basil S. Lewis⁹, David Lin¹⁰, Stephen J. Nicholls¹¹, Allan Klein⁵, Massimo Imazio¹² and John F Paolini⁶, ¹Department of Biomedical and Clinical Science, University of Milano, Fatebenefratelli Hospital, Milan, Italy, ²Kiniksa Pharmaceuticals, Ltd., Hamilton, Bermuda, ³Division of Cardiovascular Ultrasound, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, NY, ⁴VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, ⁵Department of Cardiovascular Imaging, Center for the Diagnosis and Treatment of Pericardial Diseases, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, ⁶Kiniksa Pharmaceuticals Corp., Lexington, MA, ⁷Department of Pediatric Medicine, Division of Rheumatology, Bambino Gesù Children's Hospital, Rome, Italy, ⁸Cardiology Unit, The University of Vermont Medical Center, The University of Vermont, Burlington, VT, ⁹Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center, Haifa, Israel, ¹⁰Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN, ¹¹MonashHeart, Department of Cardiology, Monash University, Clayton, Australia, ¹²University Cardiology, Cardiovascular and Thoracic Department, AOU Città della Salute e della Scienza di Torino, Torino, Italy
Background/Purpose: Post-episode tapering of Standard of Care (SoC) medication in patients with recurrent pericarditis (RP) varies considerably. Gradual tapering of corticosteroids (CS) is recommended in…
Abstract Number: 0440 • ACR Convergence 2021
Association Between Rheumatic Autoantibody Positivity and Immune-related Adverse Events
Kristen Mathias¹, Marco Lopez Velazquez¹ and Pankti Reid², ¹University of Chicago, Chicago, IL, ²University of Chicago Medical Center, Chicago, IL
Background/Purpose: The advent of immune checkpoint inhibitors (ICIs) has revolutionized cancer therapy; however, their use can lead to off-target toxicities called immune-related adverse events (irAEs)…
Abstract Number: 0650 • ACR Convergence 2021
Use, Procurement Cost, and Adverse Events from IVIg Use in Rheumatic Disease
Francisca Lambert-Fliszar¹, Evelyne Vinet², Sasha Bernatsky¹ and Arielle Mendel³, ¹McGill University, Montréal, QC, Canada, ²McGill University Health Centre, Mont Royal, QC, Canada, ³McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Intravenous immunoglobulin (IVIg) is used in several systemic rheumatic diseases due to postulated immunomodulatory properties. However, IVIg is a scarce and costly resource and…
Abstract Number: 0993 • ACR Convergence 2021
The Mechanistic Basis of anti-CD6 as a Novel Form for the Treatment of Autoimmune Diseases and Cancer
Mikel Gurrea-Rubio¹, Jeffrey Ruth¹, Qi Wu¹, Eliza Pei-Suen Tsou¹, Phillip Campbell¹, Peggy Randon¹, M.Asif Amin¹, Nora Singer², Feng Lin³ and David Fox¹, ¹University of Michigan, Ann Arbor, MI, ²The MetroHealth System, Cleveland, OH, ³Cleveland Clinic, Cleveland, OH
Background/Purpose: The use of Immune Checkpoint Inhibitors (ICIs) is limited by the induction of immune-related adverse events. CD6 is expressed by most T lymphocytes and…
Abstract Number: 1117 • ACR Convergence 2021
Ocular Scleral Pathology: Clinical Features and Systemic Treatment in 175 Patients from a Single University Center
Lara Sánchez-Bilbao¹, Vanesa Calvo-Río², José Luis Martin-Varillas³, Carmen Álvarez-Reguera¹, Alba Herrero-Morant¹, Iñigo Gonzalez-Mazon⁴, Rosalia Demetrio-Pablo¹, Miguel Ángel gonzalez-Gay⁵ and Ricardo Blanco², ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Hospital Sierrallana, Torrelavega, Spain, ⁴H. U. Marques de Valdecilla, Santander, Spain, ⁵Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Ocular scleral pathology (OSP) includes episcleritis and scleritis. Episcleritis is generally a benign disease with a self-limited course, while scleritis is a more severe…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].